Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3882347 in Healthy Participants
NCT04488770Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3882347 in urinary tract infection (UTI) (12 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events and Serious Adverse Events up to 3 months, Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance Criteria up to 3 months and 13 more. Started Aug 2020; status: completed.
02
Drugs
GSK3882347
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT04488770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488770.